Our deep local knowledge and renowned delivery focus is complemented by in-house experience and expertise in a wide variety of therapeutic areas. This is supported by close relationships with our trusted global network of key opinion leaders.
The oncology, haemato-oncology and haematology trials in various indications represent the largest portion of clinical trials conducted by Optimapharm.
Having more than 15 years of continuous experience in these therapeutic areas and after rescuing recruitment on many complex oncology and haemato-oncology trials phases 2 and 3 in Europe, we are proud on our a highly educated,experienced and pro-active clinical research teams, as well trusted and strong relationships with a global roster of key opinion leaders, to support the study execution.
Our strong presence in Central, Eastern and South-Eastern Europe benefits both sponsors and patients. Malignant diseases are the number two cause of death in these areas.
We have close relationships specialised oncology and haemato-oncology centres with proven high quality and outstanding recruitment potential. Many of these are centralised university hospitals covering large patient populations. This means we can confidently predict effective selection and activation of high-performance sites for your clinical development programs.
Years average experience of Clinical Project Managers in this indication
Over the last 15 years we have participated in some of the most renowned clinical development programs in the fields of psychiatry and neurology – helping to bring some of the leading medicines to market.
Sites that we have chosen, activated and managed have also been instrumental in rescuing recruitment targets for globally significant trials, including challenging paediatric CNS indications.
Our therapeutic area experience includes the following indications: Alzheimer’s Disease; Bipolar Disorder; Major Depression; Multiple Sclerosis; Schizophrenia; Paediatric Schizophrenia & Bipolar Disorder.
Our success is founded on our leading presence in the Adriatic region – a territory with a long and proven track record of high recruitment and quality data. High prevalence and rate of new diagnosis combine with a lack of full treatment options due to budgetary constraints in some areas. This presents a considerable opportunity for active clinical trials to deliver significant benefit patients and their families.</h5
We have established collaborative site relationships across the region with excellent recruitment potential.</h5
Central, Eastern and South-eastern Europe are our core target areas for patient recruitment. Here, due to prevalent lifestyle and dietary habits, cardiovascular diseases are the number one case of death and 48% of adults suffer from arterial hypertension.
We have established collaborative relationships with highly experienced sites, most of which are part of large university centres with thousands of daily outpatients. We are confident in their proven recruitment potential to expedite your cardiovascular study.
We cover regions with a high incidence of asthma and chronic pulmonary obstructive disease (COPD) including bronchitis and emphysema. In most countries within South-Eastern Europe, modern treatments for these diseases are not fully reimbursed, so patients are eager to participate in trials.
The region offers specialized pulmonary clinics with a proven track record of delivery high numbers of patients for major international programs. The majority of these clinics are located in university hospitals covering large patient populations.
The excellent quality of our work in this field has been assessed and confirmed by independent auditors and regulators.
The incidence of diabetes and other endocrinological conditions is rapidly increasing on a global scale. There are over 2.5 million patients diagnosed with Diabetes Type I and II in the countries covered by us.
As health budgets are limited in these areas, patients have limited access to modern treatments such as insulins, DPP-4 inhibitors and GLP1 agonists, so they are eager to participate in clinical trials.
We acquired an in-house diabetes clinical team, with a cumulative experience of over 100 studies, from a leading pharmaceutical company. Our region of operation also offers highly specialised metabolic disease centres and dedicated diabetologists with an exemplary track record of collaboration in successful clinical trials.
Rare metabolic disorders
Diabetes Type II: 120% recruitment target
Pediatric diabetes Type II: 160% recruitment target. 33% reduction in duration
Infectious diseases present one of the biggest challenges for global health, particularly in the midst of the pandemic outbreaks as COVID-19. The need for safe and effective treatments and vaccines is essential. Despite the efforts of the scientists, health system continues to express concerns for novel therapeutics to treat drug-resistant infections.
Our experienced team is leveraging strong presence in Central, Eastern and South-eastern Europe, to deliver high quality data for your clinical development strategy. We conducted studies in wide range of indications, which includes vaccines, antibacterials, antivirals, antifungals, and pneumonia.
Since the COVID-19 breakout Optimapharm has been participating in a clinical trial to assess antithrombotic treatment vs. prophylaxis in patients admitted at hospital for COVID with a high risk of thromboembolic event.
Community-Acquired Bacterial Pneumonia: 4 sites recruited 17,6% globally, 2 FDA inspections without findings
“I wanted to say thank you for your superb support and collaboration this year. I am looking forward to work with you in 2019 as it is a pleasure to work with you and your team.”
I would like to thank you all for the tremendous work done to reach this important milestone for the study in a very challenging and complex global environment. It is the first of many others that we will have to achieve together. Let's keep it up!
Clinical Project Leader, Big Pharma Company
We are very grateful for your hard work and dedication over the past few years. We are delighted to be part of this partnership and look forward to start treating patients in this new therapeutic area soon. We could not have done this without your contribution. We are very excited about the path ahead and can hardly wait to start this study.
Chief Executive Officer, Biotech Company
Corporate team and I would like to sincerely thank all the team members, both global and local, as well as the site staff, who have worked extremely hard to reach this lock! This has been achieved under difficult circumstances, being significantly earlier than planned for this discontinued study and in the middle of the COVID-19 pandemic with lockdowns or curfews in place in many of the countries. A huge thank you to all for your team spirit and commitment to reach this goal!
Clinical Project Lead, Big Pharma Company
Very pleased. Looking forward to getting the country up and running soon.
VP Global Clinical Operations, Medical Device Company